Plaunotol suppresses interleukin-8 secretion induced by Helicobacter pylori: therapeutic effect of plaunotol on H. pylori infection.
BACKGROUND
It has been suggested that gastric mucosal injury induced by Helicobacter pylori infection is mediated by interleukin-8 (IL-8).


METHODS
We studied the effect of plaunotol, a drug extracted from the Plau-noi tree of Thailand, and reported it to be effective in the treatment of ulcers, of IL-8 secretion induced by H. pylori and of the inhibitory adhesion activity of the bacterium to gastric epithelial cells. Moreover, the therapeutic effect of plaunotol on H. pylori infection was assessed by using the gnotobiotic murine model.


RESULTS
Plaunotol inhibited the growth of H. pylori (1.5 x 10(4) c.f.u./mL) at high doses (24-48 microg/mL), but not at low doses (3-6 microg/mL). Interleukin-8 secretion induced by H. pylori was inhibited by coculture with plaunotol in a dose-dependent manner. The adhesion of H. pylori to MKN45 cells was also suppressed by coculture with plaunotol in a dose-dependent manner. An in vivo study showed that plaunotol improved histological gastritis and decreased the H. pylori antibody titre.


CONCLUSIONS
These findings suggest that plaunotol has a therapeutic effect on gastritis induced by H. pylori.
Takagi
A
A
Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan. takagia@is-icc.u-tokai.ac.jp
Koga
Y
Y
Aiba
Y
Y
Kabir
A M
AM
Watanabe
S
S
Ohta-Tada
U
U
Osaki
T
T
Kamiya
S
S
Miwa
T
T
D000284:Administration, Oral; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000032:analysis; D001422:Bacterial Adhesion / Q000187:drug effects; D004224:Diterpenes; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D005233:Fatty Alcohols / Q000008:administration & dosage / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007118:Immunoassay; D016209:Interleukin-8 / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011817:Rabbits; D013274:Stomach Neoplasms / Q000378:metabolism / Q000473:pathology; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000897:Anti-Ulcer Agents; D000907:Antibodies, Bacterial; D004224:Diterpenes; D005233:Fatty Alcohols; D016209:Interleukin-8; C047686:plaunotol